Laekna Announces First Patient Dosed in South Korea in LAE201INT2101 Phase 1/2 Study ...Middle East

SHANGHAI and WARREN, N.J., Sept. 6, 2022 /PRNewswire/ -- Laekna, a clinical-stage biotechnology company dedicated to bringing ground-breaking therapies to cancer and liver fibrosis patients worldwide, announced yesterday that the first patient recently received a dose in the LAE201INT2101...

Hence then, the article about laekna announces first patient dosed in south korea in lae201int2101 phase 1 2 study was published today ( Tuesday 06/09/2022 - 12:16 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Laekna Announces First Patient Dosed in South Korea in LAE201INT2101 Phase 1/2 Study )

Also on site :

• Blessing Muzarabani ditches PSL team, joins KKR for IPL 2026
• Heart attack patients at risk as defibrillator supplies targeted in NHS hack
• Iranians tell the world: The war must continue until the Ayatollah’s regime collapses